Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Long-Term Debt Repayments (2017)

Viking Therapeutics' Long-Term Debt Repayments history spans 1 years, with the latest figure at $200000.0 for Q3 2017.

  • For Q3 2017, Long-Term Debt Repayments changed N/A year-over-year to $200000.0; the TTM value through Dec 2018 reached $200000.0, down 33.33%, while the annual FY2018 figure was $3.8 million, 4877.92% up from the prior year.
  • Long-Term Debt Repayments for Q3 2017 was $200000.0 at Viking Therapeutics, up from $100000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $200000.0 in Q3 2017 and bottomed at $100000.0 in Q2 2017.